Imugene Ltd's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong caught up with Proactive's Andrew Scott after announcing a clinical milestone has been achieved for its HER-Vaxx cancer immunotherapy in the Phase 2 gastric cancer clinical trial. Following completion of recruitment in January 2021, the important clinical endpoint of Progression Free Survival (PFS) has been met after the statistically significant required number of PFS events has occurred. Data from these 24 events will now be analysed with the final PFS readout expected within months.
Imugene CEO hails clinical milestone for HER-Vaxx cancer immunotherapy
